Merck Points To Keytruda, Zepatier Promise Coming Off Lackluster Quarter
This article was originally published in Scrip
Executive Summary
Merck & Co. Inc. urged investors to basically look past a flat fourth quarter 2015 performance on Feb. 3, emphasizing the promise of its cancer immunotherapy Keytruda (pembrolizumab) and its just-approved hepatitis C combo Zepatier (elbasvir/grazoprevir) to begin to offset revenue losses elsewhere in the portfolio, including for its top-seller Januvia (sitagliptin).